Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma.

Cancer Res Commun · 2025 · PMC11848832 · PMID 39895413

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an unexpected trendno p-value reported

Across TIL subsets, there was an unexpected trend for decreased TIL levels on treatment for the more intense QW/Q3W schedule.

also in 73 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.